Coronavirus Update: Can IL-6 Drugs Cut Deaths? Kevzara Trials Start In Worst Hit Countries
Plus: J&J's Vaccine Could Be Ready By Early 2021
Executive Summary
News from around the biopharma sector and its efforts to meet the challenges posed by the coronavirus pandemic.
You may also be interested in...
Coronavirus Update: The Hunt For A Vaccine & Non-COVID-19 Trial Plans Go Awry
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.
J&J Ramps Up Manufacturing Capacity To Produce 1 Billion Doses Of Candidate COVID-19 Vaccine
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.